These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. Lu HK; Chen YL; Chang HC; Li CL; Kuo MY J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732 [TBL] [Abstract][Full Text] [Related]
4. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829 [TBL] [Abstract][Full Text] [Related]
5. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750 [TBL] [Abstract][Full Text] [Related]
7. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324 [TBL] [Abstract][Full Text] [Related]
8. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. Tian QX; Huang GY Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268 [TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262 [TBL] [Abstract][Full Text] [Related]
10. Detection of osteoprotegerin and TNF-alpha mRNA in ankylotic Stapes footplates in connection with measles virus positivity. Karosi T; Jókay I; Kónya J; Szabó LZ; Pytel J; Jóri J; Szalmás A; Sziklai I Laryngoscope; 2006 Aug; 116(8):1427-33. PubMed ID: 16885748 [TBL] [Abstract][Full Text] [Related]
11. Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors. Garlet GP; Cardoso CR; Silva TA; Ferreira BR; Avila-Campos MJ; Cunha FQ; Silva JS Oral Microbiol Immunol; 2006 Feb; 21(1):12-20. PubMed ID: 16390336 [TBL] [Abstract][Full Text] [Related]
12. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Kaji H; Kanatani M; Sugimoto T; Chihara K Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780 [TBL] [Abstract][Full Text] [Related]
13. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Poubelle PE; Chakravarti A; Fernandes MJ; Doiron K; Marceau AA Arthritis Res Ther; 2007; 9(2):R25. PubMed ID: 17341304 [TBL] [Abstract][Full Text] [Related]
14. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478 [TBL] [Abstract][Full Text] [Related]
15. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030 [TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin is expressed in colon carcinoma cells. Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167 [TBL] [Abstract][Full Text] [Related]
17. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001 [TBL] [Abstract][Full Text] [Related]
18. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]. Ferrer Cañabate J; Tovar I; Martínez P An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784 [No Abstract] [Full Text] [Related]
19. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762 [TBL] [Abstract][Full Text] [Related]
20. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]